Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

dodecafluoropentane

ECHOGEN

dodecafluoropentane (ECHOGEN) is a ultrasound contrast agent.

EMA: withdrawn Various (V08) V08DA
Patents linked 19
Pipeline programs 11
News articles 0
Drug details — dodecafluoropentane
Class
Various (V08)
Route
—
Patents
19
Programs
11
Data quality
0.83
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

dodecafluoropentane (ECHOGEN) is a ultrasound contrast agent.

Key facts

INN dodecafluoropentane
Brand ECHOGEN
Mechanism Ultrasound contrast agent
Therapeutic class Various (V08)
ATC code V08DA

Mechanism of action

Ultrasound contrast agent

Approval history

Authority Status Date
EMA withdrawn —

Pipeline programs

Search pipeline
  1. CLI-06657AA1-03 Phase 3 · Chiesi Farmaceutici S.p.A · Fabry disease (α-galactosidase A deficiency)
  2. Open Label Topical Beremagene Geperpavec (B-VEC) Phase 3 · Krystal Biotech Netherlands · Dystrophic Epidermolysis Bullosa
  3. Open Label Selinexor Phase 2 · Karyopharm Therapeutics · Thymoma
  4. Open Mini-Laparotomy Phase 2 · Chinese Academy of · Hydrocephalus
  5. open discectomy Phase 2 · Chinese Academy of · Lumbar Disc Herniation
  6. BP1.4979 / P24-01 Phase 1 · Bioprojet · Binge eating disorder
  7. ECHO (Empowering Our Community & Health Outcomes) Phase 1 · BRIGHT MINDS BIOSCIENCES · Smoking Cessation
  8. P24-03 Phase 1 · Bioprojet · Narcolepsy, Narcolepsy with cataplexy

Related & competitor drugs

Browse all drugs
  1. besilesomab Various (V09)
  2. deferasirox Various (V03)
  3. ferric citrate coordination complex Various (V03)
  4. folic acid Various (V04)
  5. sevelamer carbonate Various (V03)
  6. sugammadex sodium Various (V03)

Related patents

Browse patents

  1. WO 2024194388

    PREPARATION DE LEVURE SACCHAROMYCES BOULARDII INACTIVEE

    Expires Wed Sep 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2023046844

    COMPOSITIONS PHARMACEUTIQUES UTILES POUR LA PRÉVENTION OU LE TRAITEMENT D'INFECTIONS VIRALES

    Expires Wed Mar 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. FR 3121841

    Traitement des hyperammoniémies

    Expires Thu Oct 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. EP 3964220

    PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON OSTEOPOROSE

    Expires Tue Mar 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. EP 3485879

    ORALE PHARMAZEUTISCHE FORMULIERUNG ENTHALTEND BAKTERIEN

    Expires Tue May 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. CA 3072544

    SACCHAROMYCES BOULARDII POUR LE TRAITEMENT DES TROUBLES DE L'HUMEUR

    Expires Wed Feb 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. CA 3065417

    TRAITEMENT DE MALADIES ASSOCIEES A UNE DYSREGULATION DE LA VOIE MTOR

    Expires Wed Dec 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. CA 3022447

    COMPOSITION UTILE POUR LA PREPARATION D'UN OVULE

    Expires Wed Oct 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. CA 2951771

    COMPOSITIONS ET METHODES PERMETTANT DE PREVENIR LES INFECTIONS

    Expires Wed Dec 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. FR 3016881

    TRAITEMENT DES DEGENERESCENCES ET DES LESIONS PHOTO-INDUITES DE LA RETINE

    Expires Thu Jul 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. EP 2886116

    Benzodioxol-Derivate zur Verwendung in der Behandlung von Aufmerksamkeitsdefizitstörung und/oder Hyperaktivität

    Expires Tue Jun 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. EP 2870969

    Pharmazeutische Zusammensetzung zur Reduzierung der adipösen Masse

    Expires Tue May 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. FR 3005577

    TRAITEMENT DE L'INCONFORT BUCCAL

    Expires Thu Nov 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. FR 2972192

    COMPOSITION PHARMACEUTIQUE DESTINEE A LA PREVENTION OU AU TRAITEMENT DES CANCERS

    Expires Thu Sep 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. CA 2724303

    COMBINAISON SYNERGIQUE DE COMPOSES ANALGESIQUES

    Expires Thu May 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. EP 2229943

    Verbindungen zur Behandlung der peripheren Neuropathie

    Expires Tue Sep 17 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. EP 2201950

    Verbindungen und Verfahren zur Behandlung von autistischen Spektrumsstörungen

    Expires Tue Jun 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. FR 2937553

    COMBINAISON SYNERGIQUE DE COMPOSES ANALGESIQUES

    Expires Thu Apr 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. EP 2179734

    Benzoxazin- und Dihydrochinazolinderivate zur Verwendung in der Behandlung von Alkoholentzugssyndrom

    Expires Tue Apr 23 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is dodecafluoropentane?

dodecafluoropentane (ECHOGEN) is a ultrasound contrast agent.

What is the brand name for dodecafluoropentane?

ECHOGEN is a marketed brand name for dodecafluoropentane. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.